Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics: Kathryn McKenzie, William Bonello, Douglas Brown

NeoGenomics announced three leadership appointments: Kathryn McKenzie as CFO, William Bonello as president of the informatics division, and Douglas Brown as chief strategy and corporate development officer. McKenzie was previously the VP of finance and chief accounting officer after joining NeoGenomics in 2017. She was also the assistant controller and director of financial reporting and treasury at Chico's FAS, and worked at Ernst and Young. 

Bonello was previously the chief strategy and corporate development officer at NeoGenomics and will continue as director of investor relations, which he's been since 2018. Before joining NeoGenomics, he was a healthcare equity analyst at Craig-Hallum and senior VP for investor relations at Laboratory Corporation of America. 

Brown is joining NeoGenomics from SVB Leerink, where he was senior managing director. He recently advised NeoGenomics on the acquisition of GenOptix and the oncology assets of Human Longevity. 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.